Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Align patent battle

This article was originally published in The Gray Sheet

Executive Summary

Invisalign dental system-maker Align Technologies infringes a patent held by orthodontics firm Ormco, the U.S. District Court for the Central District of California rules June 25. Monetary damages will be determined at a later trial. Align says it disagrees with the District Court, and will seek to overturn the decision in post-trial motions or in federal appeals court, if necessary. The verdict does not currently preclude Align from selling Invisalign, the company notes

You may also be interested in...

Danaher/Ormco versus Align Technology

Patent suit settlement announced Aug. 17 gives Danaher's Ormco subsidiary a 10% ownership stake in Align Technology, maker of the Invisalign system for treating dental misalignment. Align will give Ormco $13 million in cash as well as company stock worth $77 million under the agreement, pending anti-trust clearance. The settlement also calls for the firms to jointly develop and market an orthodontic product combining Invisalign with Ormco's Insignia custom orthodontic bracket and arch wires system "to treat the most complex cases," Align says. In June, the patent battle resulted in a ruling against Align in the U.S. District Court for the Central District of California (1"The Gray Sheet" July 6, 2009)

Finance Watch: Silverback, Kinnate, Sigilon Launch December’s First IPOs

Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.

BioCryst’s Oral Option To Take On Injectables In HAE Prophylaxis Market

Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts